A Multi-center, Double-blinded Randomized Trial for Genotype Based Personalized Prescription of Nevirapine.

Trial Profile

A Multi-center, Double-blinded Randomized Trial for Genotype Based Personalized Prescription of Nevirapine.

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Apr 2013

At a glance

  • Drugs Nevirapine (Primary) ; Lamivudine/stavudine/nevirapine; Lamivudine/zidovudine/nevirapine
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacogenomic
  • Acronyms GENPART
  • Most Recent Events

    • 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 May 2011 As of August 2010, 366 patients had been enrolled in the substudy
    • 10 May 2011 Interim results of the genetic substudy were presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases and the 27th International Congress of Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top